senescence associated long non-coding RNA 1Genealiases: SAL-RNA1 · XLOC_023166
Q-omics provides the consensus-scored SALRNA1 profile across patient tissues and cancer cell-line models. SALRNA1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SALRNA1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SALRNA1 RNA expression shows 13,403 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where SALRNA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SALRNA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SALRNA1 survival associations across molecular data types. SALRNA1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SALRNA1 RNA expression–survival associations across cancer types. High SALRNA1 expression shows unfavorable associations in KIRP, ACC, UVM, LIHC and UCEC, but favorable associations in LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SALRNA1 RNA expression.
This table summarizes SALRNA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SALRNA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SALRNA1 shows lower tumor expression in HNSC and higher tumor expression in KIRC, LUSC, BLCA, LUAD and UCEC. The KIRC box plot shows higher SALRNA1 RNA expression in tumor versus normal tissue (log2 FC = +0.025, t-test p < 0.001).
This table shows molecular features associated with SALRNA1 in patient tissues and cancer cell lines. In patient samples, SALRNA1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
